FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207067190> ?p ?o ?g. }

• W4207067190 endingPage "54" @default.
• W4207067190 startingPage "44" @default.
• W4207067190 abstract "Introduction . Pulmonary embolism (PE) accounts for about 10% in the mortality pattern among cancer patients, which is the second most frequent cause of death. Aim . To identify and characterize patients with active cancer and VTEC receiving chemotherapy (CT) based on the retrospective review of medical records provided by Moscow City Oncology Hospital No. 62 (MCOH No. 62) for the period from 01.2018 to 04.2020. Materials and methods . Medical records of 3,912 patients receiving chemotherapy treatment cycles in the departments of MCOH No. 62 were reviewed. 227 (5.8%) patients in whom the underlying disease course was complicated by VTEC were selected. Sites of primary tumours, n (%): stomach – 37 (16.3); colon and rectum – 36 (15.9); uterus, cervix, ovaries – 31 (13.7); lungs – 23 (10.1); kidneys, ureters and bladder, testicles – 19 (8.4); pancreas – 18 (7.9); soft tissues – 14 (6.2); mammary gland – 13 (5.7); lymphoma, myeloma – 8 (3.5); Ear Nose Throat (ENT) tumours – 7 (3); others – 21 (9.3). Results . The majority of patients (176 (77.5%)) had a sum Khorana score <3, 51 (22.5%) patients had Khorana scores ≥ 3, which corresponds to a high thrombotic risk. 29 (12.7%) patients died. The hospital physicians assessed the causes of death as follows: 16 patients died from pulmonary embolism, of which 13 (81%) had a sum Khorana score <3; 13 patients died due to progression of cancer. Conclusions . VTEC most commonly occurred in patients with gastrointestinal cancer (32.2%) and genito-urinary system cancer (22.1%). Half (54.5%) of VTEC occurred in the first 3 months of chemotherapy treatment. The Khorana scale is non-perfect in ‘real-life’ clinical practice (only 22.5% of patients with verified VTEC had a high thrombotic risk, and 81% of patients who died due to PE had a low and medium risk of VTEC)." @default.
• W4207067190 created "2022-01-26" @default.
• W4207067190 creator A5002850162 @default.
• W4207067190 creator A5014020285 @default.
• W4207067190 creator A5016164337 @default.
• W4207067190 creator A5070221619 @default.
• W4207067190 creator A5081852205 @default.
• W4207067190 date "2022-01-21" @default.
• W4207067190 modified "2023-10-18" @default.
• W4207067190 title "Characteristics of patients with active cancer and venous thromboembolic complications receiving a chemotherapy treatment cycle (according to the ‘real-life’ clinical practice of Publicly Funded Health Facility: Moscow City Oncology Hospital No. 62 of Moscow Healthcare Department)" @default.
• W4207067190 cites W1573083214 @default.
• W4207067190 cites W1589295587 @default.
• W4207067190 cites W1976182266 @default.
• W4207067190 cites W1995391277 @default.
• W4207067190 cites W1995828607 @default.
• W4207067190 cites W1996600303 @default.
• W4207067190 cites W2007086823 @default.
• W4207067190 cites W2022932023 @default.
• W4207067190 cites W2024789639 @default.
• W4207067190 cites W2033377234 @default.
• W4207067190 cites W2050624503 @default.
• W4207067190 cites W2063853621 @default.
• W4207067190 cites W2100997502 @default.
• W4207067190 cites W2180726212 @default.
• W4207067190 cites W2313284959 @default.
• W4207067190 cites W2562748333 @default.
• W4207067190 cites W2902078827 @default.
• W4207067190 cites W2917037555 @default.
• W4207067190 cites W2917722773 @default.
• W4207067190 cites W2990762362 @default.
• W4207067190 cites W3013809005 @default.
• W4207067190 cites W3037161220 @default.
• W4207067190 cites W3134324526 @default.
• W4207067190 cites W3205081673 @default.
• W4207067190 cites W4205361001 @default.
• W4207067190 doi "https://doi.org/10.21518/2307-1109-2021-11-2-44-54" @default.
• W4207067190 hasPublicationYear "2022" @default.
• W4207067190 type Work @default.
• W4207067190 citedByCount "1" @default.
• W4207067190 countsByYear W42070671902023 @default.
• W4207067190 crossrefType "journal-article" @default.
• W4207067190 hasAuthorship W4207067190A5002850162 @default.
• W4207067190 hasAuthorship W4207067190A5014020285 @default.
• W4207067190 hasAuthorship W4207067190A5016164337 @default.
• W4207067190 hasAuthorship W4207067190A5070221619 @default.
• W4207067190 hasAuthorship W4207067190A5081852205 @default.
• W4207067190 hasBestOaLocation W42070671901 @default.
• W4207067190 hasConcept C121608353 @default.
• W4207067190 hasConcept C126322002 @default.
• W4207067190 hasConcept C2776265017 @default.
• W4207067190 hasConcept C2776694085 @default.
• W4207067190 hasConcept C71924100 @default.
• W4207067190 hasConcept C90924648 @default.
• W4207067190 hasConceptScore W4207067190C121608353 @default.
• W4207067190 hasConceptScore W4207067190C126322002 @default.
• W4207067190 hasConceptScore W4207067190C2776265017 @default.
• W4207067190 hasConceptScore W4207067190C2776694085 @default.
• W4207067190 hasConceptScore W4207067190C71924100 @default.
• W4207067190 hasConceptScore W4207067190C90924648 @default.
• W4207067190 hasIssue "2" @default.
• W4207067190 hasLocation W42070671901 @default.
• W4207067190 hasLocation W42070671902 @default.
• W4207067190 hasOpenAccess W4207067190 @default.
• W4207067190 hasPrimaryLocation W42070671901 @default.
• W4207067190 hasRelatedWork W2138070271 @default.
• W4207067190 hasRelatedWork W2138220336 @default.
• W4207067190 hasRelatedWork W2347754406 @default.
• W4207067190 hasRelatedWork W2357848810 @default.
• W4207067190 hasRelatedWork W2375104778 @default.
• W4207067190 hasRelatedWork W2475264243 @default.
• W4207067190 hasRelatedWork W2523006498 @default.
• W4207067190 hasRelatedWork W3032655376 @default.
• W4207067190 hasRelatedWork W4248907028 @default.
• W4207067190 hasRelatedWork W4299941781 @default.
• W4207067190 hasVolume "11" @default.
• W4207067190 isParatext "false" @default.
• W4207067190 isRetracted "false" @default.
• W4207067190 workType "article" @default.